Publications by authors named "Kelcia R S Quadros"
Article Synopsis
- Dapagliflozin is being studied for its potential to improve heart function in patients with chronic kidney disease, and this research seeks to see if it has similar benefits for those on dialysis.
- The DARE-ESKD-2 trial involves adults on dialysis for over three months and randomly assigns them to receive either dapagliflozin or standard treatment for 24 weeks, measuring various heart function indicators.
- With 80 patients enrolled, the trial aims to gather new insights on how SGLT2 inhibitors like dapagliflozin could be beneficial for patients with end-stage kidney disease undergoing dialysis.
Purpose: Sodium glucose co-transporter 2 inhibitors (SGLT2i) remarkably reduced the incidence of hospitalization for heart failure and cardiovascular death of conservatively managed chronic kidney disease. We hypothesized that adding SGLT2i to standard treatment would yield cardiovascular benefits also in end-stage kidney disease (ESKD) individuals on dialysis.
Methods: The DARE-ESKD-2 Trial (NCT05685394) is an ongoing, single-center, open-label, controlled trial aimed at assessing the cardiovascular effects of dapagliflozin in ESKD on dialysis.
Background: The prevalence of aluminum (Al) intoxication has declined over the past 3 decades. However, different groups still report on the diagnosis of Al in bone. Prolonged and low-intensity exposures to Al may not be captured by serum Al measurements, preventing its proper diagnosis.
View Article and Find Full Text PDFAdvanced glycation end products (AGEs) accumulation may be involved in the progression of CKD-bone disorders. We sought to determine the relationship between AGEs measured in the blood, skin, and bone with histomorphometry parameters, bone protein, gene expression, and serum biomarkers of bone metabolism in patients with CKD stages 3 to 5D patients. Serum levels of AGEs were estimated by pentosidine, glycated hemoglobin (A1c), and N-carboxymethyl lysine (CML).
View Article and Find Full Text PDFBackground: The prevalence of anti-hepatitis C virus (HCV) positive test is higher among patients in dialysis and in kidney recipients than in general population. Hepatitis C virus infection is the main cause of chronic liver disease in renal transplant patients. Liver biopsy and virological analysis were performed to clarify the grade of liver damage in kidney recipients.
View Article and Find Full Text PDF